Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio Plc LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 2.75p 2.51p 2.99p - - - 0 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -11.0 -3.9 - 9

Motif Bio Share Discussion Threads

Showing 4251 to 4273 of 4275 messages
Chat Pages: 171  170  169  168  167  166  165  164  163  162  161  160  Older
DateSubjectAuthorDiscuss
22/8/2019
16:31
Dropping 5% on the NASDAQ before UK close does not bode well IMO
buywell3
22/8/2019
16:26
Sudden change to a narrower 2.52p v 2.53p....must have been in auction, earlier. f
fillipe
22/8/2019
16:17
Must be something going on here - the best bid/ask on show is 2.51p v 3.24p (!). Totals for the bid/ask are 496k v 398k, so there is a hunger there, f
fillipe
22/8/2019
10:49
Buywell3 Lost so much money on this there is no point in selling now anyway--very small downside, infinite if unlikely upside. I am sure I am not alone.
pianoduo
22/8/2019
09:07
It's been slow going although we do appear to be lifting off the bottom and towards 3p. f
fillipe
16/8/2019
16:03
Look at the USA market bullet it's down circa 5% Those guys know more than here IMHO no way is the FDA going to green light this If it does buywell will stop posting PROMISE
buywell3
15/8/2019
13:45
A decent rise today....for whatever reason, I know not. f
fillipe
12/8/2019
10:44
Pretty poor L2 totals at the bid/ ask - 385k v 1141k. Bests on show are 2.3 p v 2.41p. All fwiw. f
fillipe
12/8/2019
09:15
19th Sept, worrying thing is they're monies will run out by then.
zen12
11/8/2019
15:49
Is the date of the FDA meeting known yet anyone
best1467
26/7/2019
15:33
All indications are it was only the liver toxicity concerns raised by FDA in the CRL. As small crow says the trial may reinforce the FDA concerns or alleviate them. However,I believe a lot of this is about quantifying the risk of Drug Induced Liver Injury(DILI) and the lack of specific biomarkers may mean that the required trial is about generating a sufficient robust body of data. The fact no patients suffered from Hys law or specific concerns over Bilurubin levels is evidential of that outcome.
ivyspivey
26/7/2019
15:09
Now 3% lower in the USA More clued up there IMO
buywell2
26/7/2019
14:19
That's the risk!
small crow
26/7/2019
13:00
cheers small crow. What concerns me is that the results/data might confirm the FDA's concerns, rather than be simply a clinical trial prior to gaining approval.
nick rubens
26/7/2019
11:14
The purpose, presumably, is to focus on measuring more reliably any liver toxicity. Not possible to say more as we don't really know exactly what he FDA's objections were.
small crow
26/7/2019
09:37
From todays RNS "which indicated that an additional clinical trial will be required prior to granting marketing approval for iclaprim." What's the point/purpose of this clinical trial? Shouldn't it read 'clinical trial required prior to considering approval?'
nick rubens
23/7/2019
14:04
Buying now
ultra capital
19/7/2019
08:41
The way I see this latest RNS is that the only way MTFB can stay listed on NASDAQ is to do a share consolidation so as to get the US listed share price up to around $3 Will the company do that ? Might be better to just let the NASDAQ listing go
buywell2
18/7/2019
08:44
Extract from a SUMMIT RNS issued today. Ignoring the numbers, which are both worrying and mind boggling, it makes we think how difficult it must be to balance potential risk of an antibiotic against "known" benefit. "Infections caused by the bacteria Neisseria gonorrhoeae are a growing global healthcare problem, with an estimated 78 million new cases globally per year. Infection rates continue to rise sharply as highlighted by the Centers for Disease Control and Prevention (‘CDC’), which reported a 19% increase in US gonorrhoea cases in 2017, and Public Health England, which reported a 26% increase in the UK in 2018. Of great concern is the increase in resistance towards the current standard of care treatment for gonorrhoea, a combination of the broad-spectrum antibiotics, azithromycin and ceftriaxone. N. gonorrhoeae resistance rates to azithromycin are 4.4% and rising, and there is an emergence of resistance to ceftriaxone in these same strains, which are referred to as cases of ‘super gonorrhoea.’"
hashertu
17/7/2019
09:01
Read AP's post yesterday sums this up nicely, the ones in now are being played with the orchestrated rise yesterday.
zen12
16/7/2019
15:50
I have read it
amrishbhim
16/7/2019
14:49
You must be living in cloud kookoo land lol It's based on the rns..read yesterday's rns!
zen12
16/7/2019
14:35
People please stop writing comments that are based on nothing, the FDA approval will arrive before close of business of month July, they are no funding raising today or next month, speak directly to there broker house, not even considered
amrishbhim
Chat Pages: 171  170  169  168  167  166  165  164  163  162  161  160  Older
Your Recent History
LSE
MTFB
Motif Bio
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190823 07:10:05